Lepirudin for cardiopulmonary bypass surgery in a patient with terminal renal insufficiency and acute heparin-induced thrombocytopenia.
A patient with triple heart valve disease, heparin-induced thrombocytopenia, and terminal renal insufficiency was treated successfully using lepirudin for anticoagulation of cardiopulmonary bypass (CPB) and during the postoperative course. Anticoagulatory monitoring was performed with ecarin clotting time during CPB and aPTT postoperatively.
Albertinen Heart Center, Hamburg, Germany. friedrich-christian.riess@albertinen.de
F-C
FC
Riess
B
B
Dobritzsch
J
J
Kormann
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000601:surgery*; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D017202:Myocardial Ischemia / Q000601:surgery*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin